A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers

Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Study ID
NCT01748526
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to assess the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of 2 different doses of canagliflozin (JNJ-28431754) in healthy Indian volunteers.

Key Dates

Start date
Aug 31, 2008
Status verified
Jul 2016
Primary completion
Sep 30, 2008
Completion
Sep 30, 2008

Study Design

Enrollment
16 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment A
    Each volunteer will receive a single 200 mg dose of canagliflozin (JNJ-28431754) on Day 1.
  • Experimental: Treatment B
    Each volunteer will receive a single 300 mg dose of canagliflozin (JNJ-28431754) on Day 1.

Primary Outcome Measure

Plasma concentrations of canagliflozin JNJ-28431754) [ Time Frame: Up to Day 4 ]

Related Studies